TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Artrya Limited ( (AU:AYA) ) has shared an update.
Artrya Limited announced that the Huntsville Hospital Heart Centre will participate in the SAPPHIRE Study, a retrospective, multi-centre study set to commence in early 2026. The study aims to evaluate Artrya’s AI-powered Salix platform and Plaque Dispersion Score for assessing coronary artery disease risk. With the inclusion of Huntsville and Piedmont Healthcare, the study will involve 6-8 major U.S. centers, enhancing its clinical relevance and potential for adoption in cardiovascular care.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company specializing in AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiming to support clinicians in diagnosing patients more accurately and efficiently. Artrya is focused on advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 645,535
Technical Sentiment Signal: Buy
Current Market Cap: A$361.4M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.